David A. Siegel Sarepta Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 661,334 shares of SRPT stock, worth $104 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
661,334
Previous 706,134
6.34%
Holding current value
$104 Million
Previous $68.1 Million
25.74%
% of portfolio
0.2%
Previous 0.16%
Shares
14 transactions
Others Institutions Holding SRPT
# of Institutions
470Shares Held
79.3MCall Options Held
4.23MPut Options Held
1.21M-
Vanguard Group Inc Valley Forge, PA8.8MShares$1.39 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY5.96MShares$942 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X04.89MShares$773 Million0.36% of portfolio
-
Capital International Investors Los Angeles, CA4.82MShares$761 Million0.13% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.34MShares$686 Million6.78% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $13.8B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...